IGFBP7 anticorps (C-Term)
Aperçu rapide pour IGFBP7 anticorps (C-Term) (ABIN633886)
Antigène
Voir toutes IGFBP7 AnticorpsReactivité
Hôte
Clonalité
Conjugué
Application
-
-
Épitope
- C-Term
-
Specificité
- IGFBP7 antibody was raised against the C terminal of IGFBP7
-
Purification
- Affinity purified
-
Immunogène
- IGFBP7 antibody was raised using the C terminal of IGFBP7 corresponding to a region with amino acids RGGPEKHEVTGWVLVSPLSKEDAGEYECHASNSQGQASASAKITVVDALH
-
-
-
-
Indications d'application
-
WB: 1 µg/mL
Optimal conditions should be determined by the investigator. -
Commentaires
-
IGFBP7 Blocking Peptide, (ABIN5614158), is also available for use as a blocking control in assays to test for specificity of this IGFBP7 antibody
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Reconstitution
- Lyophilized powder. Add distilled water for a 1 mg/mL concentration of IGFBP7 antibody in PBS
-
Concentration
- Lot specific
-
Buffer
- PBS
-
Conseil sur la manipulation
-
Avoid repeated freeze/thaw cycles.
Dilute only prior to immediate use. -
Stock
- 4 °C/-20 °C
-
Stockage commentaire
- Store at 2-8 °C for short periods. For longer periods of storage, store at -20 °C.
-
-
- IGFBP7 (Insulin-Like Growth Factor Binding Protein 7 (IGFBP7))
-
Autre désignation
- IGFBP7
-
Sujet
- IGFBP7 contains 1 Ig-like C2-type (immunoglobulin-like) domain, 1 IGFBP N-terminal domain and 1 Kazal-like domain. It binds IGF-I and IGF-II with a relatively low affinity. IGFBP7 stimulates prostacyclin (PGI2) production.
-
Poids moléculaire
- 29 kDa (MW of target protein)
-
Pathways
- Growth Factor Binding
Antigène
-